BRIGHT HORIZONS FAMILY SOLUTIONS I (BFAM)
Sector: Consumer Discretionary
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Consumer Discretionary
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for BFAM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BFAM | Director | 76 | ["Certified Public Accountant","28 years as a partner at PricewaterhouseCoopers LLP","served clients ranging from Fortune 500 companies to rapid-growth companies","senior national leadership role for PwC’s Ethics and Compliance Group","director and Chair of the audit committee of Adaptimmune Therapeutics PLC","member of the Galera Compensation Committee","previously served as audit Chair for Tesaro Inc.","served as a trustee of Ithaca College for over 20 years"] | ["Audit"] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Alleva is a Certified Public Accountant (inactive) and spent his professional career with PricewaterhouseCoopers LLP (PwC), including 28 years as a partner, from 1971 until his retirement in 2010. At PwC he served clients ranging from Fortune 500 and multinational companies to rapid-growth companies pursuing initial public offerings. Mr. Alleva also served in a senior national leadership role for PwC's Ethics and Compliance Group to manage the design and implementation of best practice procedures, internal controls and monitoring activities, including PwC's response to inspection reports issued by the Public Company Accounting Oversight Board. Mr. Alleva currently serves as a director and Chair of the audit committee of Adaptimmune Therapeutics PLC (Nasdaq: ADAP) and on the board of Galera Therapeutics, Inc. (Nasdaq: GRTX) as well as a member of the Galera Compensation Committee. He previously served as audit Chair for Tesaro Inc. (Nasdaq: TSRO) until January 2019, Mersana Therapeutics (Nasdaq: MSRN) until January 2026 and Mirna Therapeutics, Inc. (Nasdaq: MIRN) until August 2017. He served as a trustee of Ithaca College for over 20 years, including in the Vice-Chair role for 10 years. Current public company directorships (including Bright Horizons): 3 Qualifications: Mr. Alleva brings valuable experience to the Board through his audit assurance and Sarbanes-Oxley Act expertise, as well as his professional focus on areas such as corporate governance, business strategy, risk, internal controls and financial reporting best practices.